• Explore /
  • Poster
  • / A phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor types known for association with the MYC oncogene (MYCHELANGELO I).

A phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor types known for association with the MYC oncogene (MYCHELANGELO I).

Abstract Poster

Authors

null

Ildefonso I Rodriguez-Rivera

NEXT Oncology, San Antonio, TX;

Ildefonso I Rodriguez-Rivera , Ting-Hui Wu , Rachel Ciotti , William Senapedis , Kaitlyn Sullivan , Jeff Z Gao , Sangeetha Palakurthi , Thomas McCauley , Yan Moore

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05497453

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS627)

DOI

10.1200/JCO.2023.41.4_suppl.TPS627

Abstract #

TPS627

Poster Bd #

N16

Abstract Disclosures

Similar Posters

First Author: Todd Michael Bauer

First Author: Andrae L. Vandross

First Author: Cristina Saura

First Author: Meredith McKean